- Home
- GILD vs MRVL Comparison
GILD vs MRVL Comparison
Compare GILD & MRVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | MRVL |
|---|---|---|
| Founded | 1987 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6B | 159.9B |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GILD | MRVL |
|---|---|---|
| Price | $129.55 | $275.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 32 |
| Target Price | ★ $148.39 | $120.28 |
| AVG Volume (30 Days) | 5.5M | ★ 32.2M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.55% | 0.15% |
| EPS Growth | ★ 1684.21 | 400.98 |
| EPS | ★ 1.61 | 0.04 |
| Revenue | ★ $24,689,000,000.00 | $8,194,600,000.00 |
| Revenue This Year | $4.68 | $35.14 |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | ★ $80.23 | $7,907.75 |
| Revenue Growth | 9.98 | ★ 42.09 |
| 52 Week Low | $107.19 | $61.44 |
| 52 Week High | $157.29 | $324.20 |
Technical Indicators
Market Signals| Indicator | GILD | MRVL |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 69.00 |
| Support Level | $128.33 | $76.10 |
| Resistance Level | $137.35 | N/A |
| Average True Range (ATR) | 3.01 | 21.23 |
| MACD | -0.18 | 9.74 |
| Stochastic Oscillator | 27.44 | 69.12 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.